Discover 3,012 paid clinical trials in Riverside, California. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 3,012
Molecular Genetics Studies of Cancer Patients and Their Relatives
for
Malignant Neoplasm
Location: Orange CA, Laguna Hills CA, Fullerton CA, Duarte CA,
Sponsor: City of Hope Medical Center
Sex: All
Age: 0+
Code: NCT04185935
Recruiting
Perivenous Dexamethasone Therapy: Examining Reduction of Inflammation After Thrombus Removal to Yield Benefit in Acute Femoropopliteal DVT
for
Thrombosis, Deep Vein, Iliofemoral; Thrombosis
Location: Orange CA, Scottsdale AZ, Seattle WA, Arlington TX,
Sponsor: Mercator MedSystems, Inc.
Sex: All
Age: 18 - 70+
Code: NCT04862468
Phase 2, Recruiting
Treating Pulmonary Embolism With Laguna Thrombectomy System (TRUST)
for
Pulmonary Embolism
Location: Orange CA, Mission Viejo CA, Irvine CA, Long Beach CA,
Sponsor: Innova Vascular, Inc.
Sex: All
Age: 18 - 70+
Code: NCT06041594
Recruiting
A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
for
Non Small Cell Lung Cancer (Squamous or Non Squamous),
Location: Orange CA, Glendale CA, Albuquerque NM, Pueblo CO,
Sponsor: Eikon Therapeutics
Sex: All
Age: 18+
Code: NCT07365319
Phase 2, Phase 3, Recruiting
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
for
Non-Small-Cell Lung Cancer,
Location: Orange CA, Fullerton CA, Los Angeles CA,
Sponsor: ArriVent BioPharma, Inc.
Sex: All
Age: 18+
Code: NCT07185997
Phase 3, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Assessment of Support With Impella® Best Practices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
for
AMI Cardiogenic Shock
Location: Orange CA, Torrance CA, Albuquerque NM, Portland OR,
Sponsor: Abiomed Inc.
Sex: All
Age: 18+
Code: NCT06964685
Recruiting
Machine Learning Prediction of Possible Central Line Associated Blood Stream Infections and Rate of Reduction
for
Central Line Associated Blood Stream Infections (CLABSI)
Location: Orange CA, Fullerton CA, Mission Viejo CA,
Sponsor: Swedish Medical Center
Sex: All
Age: 18+
Code: NCT07108660
Recruiting
Testing Tumor Tissue and Blood to Help Select Personalized Treatments for Patients With Suspected Lung Cancers
for
NSCLC
Location: Orange CA, Los Angeles CA, Davis CA, Seattle WA,
Sponsor: Lung Cancer Mutation Consortium
Sex: All
Age: 0+
Code: NCT04712877
Recruiting
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
for
Advanced Malignant Solid Neoplasm,
Location: Orange CA, Los Angeles CA, Santa Monica CA,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 0+
Code: NCT05564377
Phase 2, Recruiting
Suramin for the Treatment of Autism Trial: KZ101 in a Male Pediatric Population With Autism Spectrum Disorder (ASD)
for
Autism Spectrum Disorder (ASD)
Location: Orange CA, Baltimore MD
Sponsor: Children's Hospital of Orange County
Sex: Male
Age: 5 - 14
Code: NCT06866275
Phase 2, Recruiting
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
for
Pancreatic Acinar Cell Carcinoma,
Location: Orange CA, Las Vegas NV, Kingman AZ, Modesto CA,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT04858334
Phase 2, Recruiting
Sacral Neuromodulation for Male Overactive Bladder (MOAB)
for
Overactive Bladder, Urinary Urgency Incontinence,
Location: Murrieta CA, Scottsdale AZ, Mountain View CA,
Sponsor: Axonics, Inc.
Sex: Male
Age: 18+
Code: NCT06511141
Recruiting
Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer